Clinical Trial Update: An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert [Phase 2]

View source ↗

Summary

Open-label extension to assess safety of the 13 mg bimatoprost ocular insert in patients with primary open-angle glaucoma or ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• bimatoprost ocular insert (13 mg) (bimatoprost)

Snippet

Sponsor: ForSight Vision5, Inc. | Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2019-02-26